Ropeginterferon alfa 2b is a longer acting form of pegylated interferon. It has very recently been approved for marketing in the EU for the treatment of Polycythemia Vera under the name “Besremi”. Read the full news announcement here.
The day prior to the MPNAE&I Patient Program in Melbourne, Australian MPN clinicians and researchers met with some US counterparts to share knowledge and ideas. In the photo below, Dr Ruben Mesa speaks about the unmet needs of MPN patients, particularly those with Myelofibrosis. He discussed the role of Ruxolitinib, Interferon and clinical trials. He addressed the question of what would constitute failure of Ruxolitinib treatment, and when it might be appropriate to continue Ruxolitinib despite suboptimal symptom or spleen control, or hematological toxicity in this group of patients. Thanks again to Ann Brazeau and MPNAE&I for making this possible.
By Ann Brazeau, CEO, MPN Advocacy and Education International
MPN Advocacy and Education International hosts several patient/caregiver educational programs per year. Although most take place in the United States, their goal to expand to other countries where MPN groups are interested in partnering to benefit their MPN Communities has been a priority.
Through collaboration with the MPN Alliance Australia, the first patient/caregiver program was held in Melbourne on the 28th April, 2017. MPN specialists from Australia joined U.S. specialists to share up-to-date, relevant information to over 150 patients and caregivers.
Empowering patients with the knowledge they need to better understand the complexities of MPNs, is what MPN Advocacy and Educational International hopes to achieve at these events. Partnerships are essential to the success of these very important programs. Imparting valuable, reliable information to the MPN Communities around the world helps bridge the gap to understanding what is being done, and identifying unmet needs.
In the early days of my work in MPN little was being shared among researchers and academic institutions. Today, it is a common practice. Recognizing the importance and value in collaborating, researchers and clinicians are much more amenable and grateful for opportunities to share their experiences and findings. Thus, a physician/researcher meeting was held the afternoon before the patient event.
A half-day strategy meeting with the MPN Alliance Australia proved to be meaningful and productive. Their dedication and commitment to the patients and caregivers in Australia is evident in the many hours they volunteer each week.
We are proud to have been a part of this experience and were happy to pull this event together with our partners, MPN Alliance Australia.
The MPN Alliance Australia works in partnership with the Leukaemia Foundation, who manage the dedicated MPN Fund and provide governance.